Icahn School of Medicine at Mount Sinai New York, New York
We have been using monocolonal antibodies to block one cytokine (TNF) for nearly 25 years. In the last 5 years we have been using ustekinuab, which blocks interleukin-12 and -23, for Crohn's disease, and in the last 3 years for ulcerative colitis. Get ready for the latest anti-interleukin antbodies: the anti-IL-23 antibodies. How are they different from TNF inhibitors, and from ustekinumab? How are they best used in clinical practice?
This session is supported by a joint educational grant from Janssen Scientific Affairs, LLC and Eli Lilly and Company.
Learning Objectives:
Describe the mechanism and rationale behind the development of targeted IL-23 inhibitors
• Evaluate current efficacy and safety data for approved and emerging IL-12/23 and IL-23 inhibitors for the management of IBD
• Develop personalized treatment strategies using IL-12/23 or -23 inhibitors for patients with IBD using data-driven decision making